{"schema_version":"secwatch.filing_event.v1","accession":"0000914121-22-000084","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.750948+00:00","generated_at":"2026-06-27T20:07:20.641638+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AngioDynamics Q2 revenue +7.6% to $78.3M; adj. loss per share $0.02; guidance cut on margin and EPS","bullets":["Net sales $78.3M (+7.6% YoY); Med Tech +36.4% driven by atherectomy/thrombectomy.","GAAP net loss $8.4M (-$0.21/share) vs loss $4.3M (-$0.11) a year ago; adjusted loss per share $0.02.","Gross margin 51.8%, down 340 bps due to supply chain, labor shortages, raw material/freight costs.","FY2022 revenue guidance reaffirmed $310-315M; gross margin cut to 52-54% from 55%; adj. EPS guidance to ($0.02)-$0.02.","Full market release of AlphaVac Thrombectomy device commenced after quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0000914121-22-000084","json":"https://secwatch.observer/filing/0000914121-22-000084.json","markdown":"https://secwatch.observer/filing/0000914121-22-000084.md","text":"https://secwatch.observer/filing/0000914121-22-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000091412122000084/0000914121-22-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000091412122000084/p57239050-8ki.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:07:20.641638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}